drugset / Trial / NCT07456891
Remibrutinib Open Label Roll-over Post-trial Access Protocol
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Multi-center, open-label roll-over post-trial access protocol to provide remibrutinib treatment and collect long-term safety for up to three years for participants who are currently receiving remibrutinib treatment in a Novartis-sponsored study, who are benefiting from treatment with remibrutinib, and are unable to access remibrutinib treatment outside of a clinical study.
Timeline
- Start
- 2026-04-16
- Primary completion
- 2033-01-30
- Completion
- 2033-01-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Remibrutinib | Small molecule | — | — |
Indications
No indication recorded.